மரபணு ஆம்ப் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates
News provided by
Share this article
Share this article
SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/  Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research collaboration for the discovery of innovative cancer therapies in the expanding antibody-drug conjugates (ADC) class. This research collaboration has been undertaken with the goal of further exploiting this new therapeutic class, potentially offering cancer patients future treatments that efficiently target cancer cells while avoiding impact on healthy ....

Jisoo Pae , Scioto Bioscience , Genome Company Introduction , Genome Company , Antibody Drug Conjugate , Genome Amp Company , ஜிசூ ப்ாே , சியோட்டோ உயிர் அறிவியல் , மரபணு நிறுவனம் அறிமுகம் , மரபணு நிறுவனம் , மரபணு ஆம்ப் நிறுவனம் ,